Terray Therapeutics closes $120 million financing

California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million.

The funding will progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova, which it uses to power both internal and partnered programs. The company says it is focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale,

Leading the round were new investor Bedford Ridge Capital and existing investor NVentures (NVIDIA’s venture capital arm), with participation from new and existing investors including Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures. Sid Shenai, who partnered with Bedford Ridge Capital on this financing, will join Terray’s Board of Directors.